Moderate to Severe Glabellar Lines Clinical Trial
Official title:
A Phase I/II,Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Safety,Efficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate to severe glabellar lines.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05463965 -
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT06151561 -
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT02353871 -
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06199336 -
A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT06354127 -
DWP450 for Treating Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03970876 -
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
|
Phase 1/Phase 2 |